AI assistant
Arcus Biosciences, Inc. — Director's Dealing 2022
Jun 16, 2022
31966_dirs_2022-06-16_d47113f0-8fb7-4350-9bc2-d1241a6b35bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2022-06-14
Reporting Person: PERLMAN ANDREW J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-14 | Common Stock | A | 4100 | $0.00 | Acquired | 11125 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-14 | Stock Option (Right to Buy) | $20.62 | A | 16800 | Acquired | 2032-06-13 | Common Stock (16800) | Direct |
Footnotes
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: Includes 1,500 and 3,000 shares of restricted stock units (previously reported) that vested on December 15, 2021 and June 3, 2022, respectively.
F3: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.